Search

Publications

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
P. Sonneveld, A. Chanan-Khan, K. Weisel, A. K. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder, M.

Read more

Publications

The Reporting, Use, and Validity of Patient-Reported Outcomes in Multiple Myeloma in Clinical Trials: A Systematic Literature Review
Salek, S. ; Ionova, T. ; Oliva, E. N. ; Andreas, M. ; Skoetz, N. ; Kreuzberger, N. ; Laane, E.

Read more

The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.

Read more

EHA-ISHBT Hematology Tutorial on Hematological Disorders

Dates: February 28-29, 2020
Location: Chandigarh, India
Chairs: N Varma, P Malhotra, J Gribben

Organized by: European Hematology Association (EHA) & Indian Society of Hematology and Blood Transfusion (ISHBT)

EHA will join ISHBT for a fourth time to organize the EHA-ISHBT Hematology Tutorial, this time in Chandigargh,…

Read more

Dates and deadlines

You may find in this page all the dates and deadlines related to the EHA2024 Hybrid Congress.  All deadlines, except if mentioned differently, end at 23:59 CET/CEST.  

The timelines will be updated regularly.

Read more

Pieter Sonneveld appointed Officer in the Order of Orange-Nassau

The EHA Board congratulates former EHA President Professor Pieter Sonneveld on his appointment as an Officer of the Order of Orange-Nassau by His Majesty King Willem-Alexander of the Netherlands.

Read more